44.69
전일 마감가:
$43.43
열려 있는:
$43.04
하루 거래량:
349.18K
Relative Volume:
0.50
시가총액:
$2.45B
수익:
-
순이익/손실:
$-146.66M
주가수익비율:
-16.23
EPS:
-2.7541
순현금흐름:
$-133.21M
1주 성능:
+2.80%
1개월 성능:
+22.19%
6개월 성능:
-1.17%
1년 성능:
+16.04%
Apogee Therapeutics Inc Stock (APGE) Company Profile
명칭
Apogee Therapeutics Inc
전화
650-394-5230
주소
221 CRESCENT ST., WALTHAM
APGE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
APGE
Apogee Therapeutics Inc
|
44.64 | 2.45B | 0 | -146.66M | -133.21M | -2.7541 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
454.86 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.28 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
326.40 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
553.88 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.85 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-13 | 개시 | Citigroup | Buy |
2024-11-25 | 개시 | Canaccord Genuity | Buy |
2024-05-10 | 개시 | BofA Securities | Buy |
2023-12-20 | 개시 | BTIG Research | Buy |
2023-08-08 | 개시 | Guggenheim | Buy |
2023-08-08 | 개시 | Jefferies | Buy |
2023-08-08 | 개시 | Stifel | Buy |
2023-08-08 | 개시 | TD Cowen | Outperform |
2023-08-08 | 개시 | Wedbush | Outperform |
모두보기
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
Rhumbline Advisers Has $2.03 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Contrasting argenx (NASDAQ:ARGX) and Apogee Therapeutics (NASDAQ:APGE) - Defense World
APGE Stock Update: Apogee Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Apogee Therapeutics stock maintains buy rating ahead of key trial data - Investing.com Canada
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by California State Teachers Retirement System - Defense World
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? - sharewise
Insider Sell: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Ameriprise Financial Inc. Makes New $259,000 Investment in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference - GlobeNewswire
4,824 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by BNP Paribas Financial Markets - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Bank of America Corp DE - Defense World
Millennium Management LLC Has $5.90 Million Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
(APGE) Investment Analysis and Advice - news.stocktradersdaily.com
Stifel maintains Buy rating, $35 target on Apogee Therapeutics stock By Investing.com - Investing.com India
Stifel maintains Buy rating, $35 target on Apogee Therapeutics stock - Investing.com
D. E. Shaw & Co. Inc. Has $445,000 Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Boosts Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $94.60 - Defense World
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet - MSN
Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire
How To Trade (APGE) - news.stocktradersdaily.com
Northern Trust Corp Grows Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Q1 Earnings Forecast for APGE Issued By Wedbush - Defense World
Wedbush Equities Analysts Lift Earnings Estimates for APGE - Defense World
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma - marketscreener.com
Apogee Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class (APGE) - Seeking Alpha
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewswire
BTIG maintains Apogee Therapeutics stock Buy rating, $100 target By Investing.com - Investing.com India
BTIG maintains Apogee Therapeutics stock Buy rating, $100 target - Investing.com
Why Is Apogee Therapeutics Stock Trading Higher On Monday? - Benzinga
Apogee Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Apogee Therapeutics reports positive results from asthma treatment trial - Seeking Alpha
Apogee Therapeutics (APGE) Reports Promising Phase 1b Trial Resu - GuruFocus
Apogee (APGE) Sets Sights on Transformative Achievements in 2025 - GuruFocus
Apogee Therapeutics Q1 Loss Widens - marketscreener.com
Apogee Therapeutics Reports Positive Phase 1b Trial Results - TipRanks
Apogee Therapeutics, Inc. SEC 10-Q Report - TradingView
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $55.3M, vs. FactSet Est of $72.3M Loss - marketscreener.com
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma - The Manila Times
Apogee Therapeutics Reports Positive Phase 1b Trial Results for APG808 in Asthma, Highlighting Durable FeNO Suppression and Potential for Extended Dosing Intervals - Nasdaq
Apogee Therapeutics (APGE) Projected to Post Quarterly Earnings on Monday - Defense World
Apogee Therapeutics chief medical officer sells shares totaling $97,418 By Investing.com - Investing.com Nigeria
Apogee Therapeutics chief medical officer sells shares totaling $97,418 - Investing.com Australia
Apogee Therapeutics Inc (APGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Apogee Therapeutics Inc 주식 (APGE) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Dambkowski Carl | Chief Medical Officer |
May 07 '25 |
Sale |
35.75 |
2,725 |
97,419 |
244,448 |
Dambkowski Carl | Chief Medical Officer |
Apr 02 '25 |
Sale |
36.22 |
3,860 |
139,801 |
247,173 |
자본화:
|
볼륨(24시간):